Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722484 | 1.00 | ESR1 (0.43) | ESR1ESR2MGLLMEN1KMT2A | |
| SCHEMBL12016645 | 0.77 | MGLL (0.53) | ESR1ESR2MGLLMEN1KMT2A | |
| SCHEMBL722830 | 0.76 | CASP3 (0.37) | MTORSMN1; SMN2 | |
| SCHEMBL722831 | 0.76 | CASP3 (0.37) | MTORSMN1; SMN2 | |
| SCHEMBL29836030 | 0.76 | HTT (0.47) | MEN1KMT2ACYP2D6CYP2C19MTOR | |
| SCHEMBL168765 | 0.76 | HTT (0.47) | MEN1KMT2ACYP2D6CYP2C19MTOR | |
| SCHEMBL12004629 | 0.76 | MGLL (0.51) | ESR1ESR2MGLLMEN1KMT2A | |
| SCHEMBL6850487 | 0.76 | MGLL (0.51) | ESR1ESR2MGLLMEN1KMT2A | |
| SCHEMBL167694 | 0.72 | GRM1 (0.51) | — | |
| SCHEMBL68996 | 0.71 | ALOX15 (0.43) | ESR1ESR2MEN1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| CN-114591311-A | Compounds that modulate intracellular calcium | 钙医学公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10336738-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-11-12 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9079891-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130345240-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130345193-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8546403-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2609095-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2563776-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027710-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322012-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-10336738-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-20130345193-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-20150344469-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-20120053210-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
| US-20130345240-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ESR1 2379/4885ESR2 1179/4885MGLL 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.